Wednesday, January 23, 2019
Biohaven allowed to proceed with BHV-3241 Phase 3 clinical trial
Biohaven Pharmaceutical (BHVN)announced the FDA has notified the company that it may proceed with its clinical investigation of BHV-3241, a novel myeloperoxidase, or MPO, inhibitor, which Biohaven is developing as a potential treatment for multiple system atrophy, or MSA. The FDA May Proceed Letter was received following Biohaven’s reactivation of the investigational new drug, or IND, application initially filed by AstraZeneca (AZN) prior to licensing the compound to Biohaven.
https://thefly.com/landingPageNews.php?id=2852065
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.